$QTTB News

Q32 Bio To Reveal 36-Week Topline Results From Part B Of The SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe Aa On July 13, 2026

Q32 Bio Files Prospectus For $300M Offering

Why Is Q32 Bio Stock Gaining Friday?

QTTB Stock Hits 18-Month High, Heads Toward Recording Its Best Ever Month – What’s Driving The Investor Optimism?

Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB)

Q32 Bio Announces $55 Million Private Placement Financing

Q32 Bio Inks Securities Purchase Agreement With New, Current Institutional Investors For ~$55M Private Placement Of Common Stock, Pre-Funded Warrants

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet

Mizuho Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $14

Cantor Fitzgerald Initiates Coverage On Q32 Bio with Overweight Rating

Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade

HC Wainwright & Co. Reiterates Buy on Q32 Bio, Maintains $13 Price Target

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Q1 EPS $(0.54) Beats $(0.68) Estimate

Q32 Bio Files Prospectus To Launch New $75M At-The-Market Offering Program

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Q32 Bio shares are trading lower after the company announced that it entered into a controlled equity offering agreement with Cantor Fitzgerald for up to $14.2 million of shares.

Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?

Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive

Q32 Bio Files Prospectus To Offer And Sell Common Stock Up To $14.2M Through Cantor